Taylor Blaine Hudson, LGPC | |
35 Kensington Pkwy, Abingdon, MD 21009-1851 | |
(410) 671-2705 | |
Not Available |
Full Name | Taylor Blaine Hudson |
---|---|
Gender | Female |
Speciality | Counselor - Mental Health |
Location | 35 Kensington Pkwy, Abingdon, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1639956691 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | LGP14223 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Taylor Blaine Hudson, LGPC 1864 Bramble Brook Ln, Bel Air, MD 21015-2540 Ph: (443) 987-3431 | Taylor Blaine Hudson, LGPC 35 Kensington Pkwy, Abingdon, MD 21009-1851 Ph: (410) 671-2705 |
News Archive
During the 2008 Beijing Olympics, changes in air pollution were associated with changes in biomarkers of systemic inflammation and thrombosis (formation of blood clot) as well as measures of cardiovascular physiology in healthy young persons, according to a study in the May 16 issue of JAMA, a theme issue on Global Health.
Omeros Corporation today announced positive data from the Company's Phase 1 clinical trial evaluating the pharmacokinetics of OMS824, the lead compound in Omeros' phosphodiesterase 10 program, further supporting that OMS824 can achieve superior target engagement with lesser side effects compared to other PDE10 inhibitors in development.
Researchers from the Medical Research Council and University of Cambridge, led by Dr Ken Ong, studied the association between mother's age at first menstruation, mother's adult body size and obesity risk, and children's growth and obesity risk in 6,009 children from the UK Avon Longitudinal Study of Parents and Children (ALSPAC) in Bristol.
Today, the U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression.
Myriad Genetics, Inc. today announced that its Tumor BRACAnalysis CDx- companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations by 44 percent in women with ovarian cancer. Data from this new study were presented at the 2014 European Society for Medical Oncology annual meeting in Madrid, Spain.
› Verified 9 days ago
Erin Michele Sayre, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1301 Continental Dr Ste 101, Abingdon, MD 21009 Phone: 667-600-3220 | |
Mr. Arthur Harry Burris, LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 3105 Emmorton Rd, Abingdon, MD 21009 Phone: 410-569-5900 Fax: 410-569-7751 | |
Emily Bermudez Fadgen, ATR-BC, LCPAT Counselor Medicare: Not Enrolled in Medicare Practice Location: 3508 Back Pointe Ct Unit 1b, Abingdon, MD 21009 Phone: 215-906-0237 | |
Mrs. Alla Musshorn, LGPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1301 Continental Dr Ste 101, Abingdon, MD 21009 Phone: 667-600-3214 | |
Ayzha Gabrielle Corbett, LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 2901 Islay Ct, Abingdon, MD 21009 Phone: 667-320-2173 | |
Victoria Swift, Counselor Medicare: Not Enrolled in Medicare Practice Location: 3437 Bodden Way Apt 172, Abingdon, MD 21009 Phone: 443-807-9951 | |
Mrs. Kathleen L Mauck, LCSW-C Counselor Medicare: Not Enrolled in Medicare Practice Location: 3101 Holly Berry Ct, Abingdon, MD 21009 Phone: 410-491-0185 |